| A472 |
NG-101 Biosimilar（Anti-RTN4 / NOGO Reference Antibody）
Featured
|
|
|
| A473 |
LK-1 Biosimilar(Anti-S100A4 Reference Antibody)
Featured
|
|
|
| A474 |
CDX-0158 Biosimilar(Anti-SCFR / c-Kit / CD117 Reference Antibody)
Featured
|
|
|
| A475 |
LOP628 Biosimilar(Anti-SCFR / c-Kit / CD117 Reference Antibody)
Featured
|
|
|
| A476 |
Wuhan U. patent anti-Nav1.9 Biosimilar（Anti-SCN11a / Nav1.9 Reference Antibody）
Featured
|
|
|
| A477 |
Duke anti-NAv1.7 Biosimilar（Anti-SCN9a / Nav1.7 Reference Antibody）
Featured
|
|
|
| A478 |
Pepinemab Biosimilar（Anti-SEMA4D / CD100 Reference Antibody ）
Featured
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D. |
|
| A479 |
Sanofi patent anti-PAI-1 Biosimilar（Anti-SERPINE1 Reference Antibody）
Featured
|
|
|
| A480 |
Abbv-011 Biosimilar（Anti-SEZ6 Reference Antibody）
Featured
|
|
|
| A481 |
Pritoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody )
Featured
|
Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1. |
|
| A482 |
Setoxaximab Biosimilar(Anti-Shiga toxin (E.coli) Reference Antibody)
Featured
|
Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1. |
|
| A483 |
MVT-5873 Biosimilar（Anti-Sialyl-Lewis A Reference Antibody）
Featured
|
|
|
| A484 |
AB-25E9 Biosimilar(Anti-Siglec-15 / CD33L3 Reference Antibody)
Featured
|
|
|
| A485 |
NC-318 Biosimilar(Anti-Siglec-15 / CD33L3 Reference Antibod)
Featured
|
|
|
| A486 |
Medimmune patent anti-Siglec-15 Biosimilar（Anti-Siglec-15 / CD33L3 Reference Antibody）
Featured
|
|
|
| A487 |
Epratuzumab Biosimilar（Anti-Siglec-2 / CD22 Reference Antibody）
Featured
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. |
|
| A488 |
Pinatuzumab Biosimilar（Anti-Siglec-2 / CD22 Reference Antibody）
Featured
|
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL). |
|
| A489 |
Inotuzumab-CLM Biosimilar（Anti-Siglec-2 / CD22 Reference Antibody）
Featured
|
|
|
| A490 |
NCI m971 Biosimilar（Anti-Siglec-2/CD22 Antibody ）
Featured
|
|
|
| A491 |
NCI m972 Biosimilar（Anti-Siglec-2/CD22 Antibody ）
Featured
|
|
|
| A492 |
IMGN779 Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
|
|
| A493 |
Vadastuximab Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. |
|
| A494 |
Gemtuzumab Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. |
|
| A495 |
Refanezumab Biosimilar（Anti-Siglec-4a / MAG Reference Antibody）
Featured
|
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke. |
|
| A496 |
Lirentelimab Biosimilar（Anti-Siglec-8 Reference Antibody）
Featured
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis. |
|
| A497 |
BI 765063 Biosimilar（Anti-SIRPa / CD172a Reference Antibody）
Featured
|
|
|
| A498 |
Hospital for Sick Children patent anti-SIRPA Biosimilar（Anti-SIRPa / CD172a Reference Antibody）
Featured
|
|
|
| A499 |
KWAR 23 Biosimilar（Anti-SIRPg / CD172g Reference Antibody）
Featured
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research. |
|
| A500 |
SGN-CD352A Biosimilar（Anti-SLAMF6 / CD352 Reference Antibody）
Featured
|
|
|
| A501 |
Azintuxizumab Biosimilar（Anti-SLAMF7 / CS1 Reference Antibody）
Featured
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin. |
|
